DEA Should Work With States to Get Rescheduling Right

September 27, 2026

Photo by DΛVΞ GΛRCIΛ via Pexels.

Mark your calendar for April 28, 2026. That's the date the DEA's final order takes effect, moving marijuana from Schedule I to Schedule III of the Controlled Substances Act for two specific categories: FDA-approved marijuana drug products and marijuana obtained through a state medical marijuana license. The order followed a December 18, 2025 executive action from President Trump directing the attorney general to move rescheduling along, and it landed in the Federal Register with a firm effective date and comparatively little instruction on how state programs are supposed to actually operationalize it.

That gap is the subject of a recent op-ed from Gillian Schauer, executive director of CANNRA, the nonpartisan association of state cannabis regulators. Her account is not a policy complaint about where marijuana sits on the schedule. It's a much more mundane and more urgent problem: CANNRA reached out to DEA offering to help coordinate implementation, and got mostly silence back at the headquarters level. That silence might sound like a bureaucratic footnote. For the people running state medical programs and the licensees who depend on them, it's the difference between a manageable transition and a scramble that starts with confusion and ends with compliance failures nobody intended.

What the Rescheduling Order Actually Changes

Photo by Jeff Trierweiler via Unsplash.

The rule itself is narrower than a lot of the headlines around it suggest. Effective April 28, 2026, marijuana shifts from Schedule I to Schedule III, but only for two categories of product: those that have gone through FDA approval as drug products, and marijuana obtained by a patient or caregiver under a legitimate state medical marijuana license. Everything else -- the unlicensed marijuana crop grown on a farm without a medical program tie-in, bulk cannabis moving through commercial channels, adult-use product sold at a recreational dispensary, and most cannabis derivatives -- stays exactly where it was, classified as Schedule I. That distinction matters enormously for an industry where medical and recreational products often move through the same facilities and sometimes the same shelves.

CANNRA's Outreach and DEA's Silence

Photo by Chethana Muniswamygowda via Unsplash.

CANNRA isn't a trade association or a lobbying shop, and that distinction is central to understanding why its outreach to DEA carries weight. Its members are the actual regulatory agencies charged with implementing cannabis and hemp law on the ground, representing primary regulatory bodies in more than 45 U.S. states and territories, plus international counterparts in Canada, the Netherlands, Malta, and Albania. These are the people who write the licensing rules, run the background check systems, and field the calls when an operator doesn't know what box to check. When the final rescheduling rule published, CANNRA reached out to DEA specifically to offer coordination help -- the kind of technical, unglamorous work of translating a federal legal change into workable guidance for fifty different state systems.

The Unanswered Questions Piling Up in States

Schauer's account lays out a list of unresolved questions that read less like abstract legal puzzles and more like items an operator needs answered before April 28, 2026 arrives. Can a licensee in a state with combined medical and recreational authority still get a DEA registration under the new Schedule III framework, or does the mixed license structure disqualify them? Will DEA register applicants whose owners or key employees have past criminal convictions, given that a number of state medical programs deliberately built pathways for people with those records to participate in the legal industry? A federal requirement that medical marijuana identification cards list the name of the recommending practitioner runs headlong into the reality that most state statutes don't require that information on the card at all. Schauer frames the ask plainly: states need federal guidance with enough lead time for legislatures and regulators to adjust their laws, and for operators to adjust how they actually run their businesses. Absent that, states risk falling out of compliance with federal registration expectations through no fault of their own -- simply because nobody told them what compliance looks like.

A Pattern of Coordination Gaps at DEA and FDA

Photo by NORTHFOLK via Unsplash.

This isn't happening in a vacuum. A GAO report released within the past week found that DEA lacks comprehensive, documented policies for evaluating and scheduling controlled substances, and that FDA has similar gaps on its side of the same process. The interagency agreement that's supposed to govern how FDA and NIDA coordinate on scheduling recommendations is more than 40 years old, and it references offices that have since been dissolved or restructured out of existence. Notably, DOJ, DEA, HHS, FDA, and NIH all agreed with GAO's recommendations to fix this, which is itself telling -- the agencies aren't disputing that the coordination infrastructure is outdated, they're just acknowledging it after the fact rather than building it before decisions land. Seen against that backdrop, CANNRA's experience getting rebuffed at DEA headquarters looks less like a one-off oversight and more like a symptom of how these agencies handle scheduling decisions generally, whether or not marijuana is involved.

What's at Stake if DEA Stays Quiet

None of this changes the calendar. April 28, 2026 is fixed regardless of whether federal guidance ever materializes, which leaves a narrow window for fifty-plus state programs -- each with its own licensing structure, background check standards, and patient card requirements -- to reconcile their rules with a federal framework that assumes a level of uniformity that doesn't exist. Operators could end up facing DEA registration denials or compliance gaps they had no reasonable way to see coming, simply because the state rules they've been following for years don't match assumptions baked into the federal order. Layered on top of that is the separate, broader Schedule I-to-III rulemaking that's still pending after DEA's 11-day administrative hearing wrapped up in July, with final arguments filed in August. That larger case remains undecided while DEA waits on a recommendation from the presiding administrative law judge, meaning the current rescheduling order is playing out against an already uncertain regulatory backdrop. As always, cannabis law varies by state and continues to shift quickly at the federal level, so anyone affected should confirm current requirements directly with their state regulator rather than relying on general reporting.

What CANNRA is asking for isn't a policy carve-out or a delay in implementation -- it's a seat at the table to help translate a federal rule into something state agencies and licensees can actually follow. That's a low bar, procedurally speaking, and it's one DEA headquarters has yet to clear, even as certain DEA field divisions have managed to work productively with state regulators on their own initiative. The disconnect between field-level cooperation and headquarters silence is its own small window into how uneven this process has been.

The GAO findings make clear this isn't a marijuana-specific failure of imagination at DEA. It's what happens when scheduling decisions move on a political timeline without the coordination infrastructure to match -- an outdated interagency agreement, no comprehensive evaluation policy, and agencies that agree in principle they should fix this without having fixed it yet. Marijuana rescheduling just happens to be the highest-profile place that dysfunction is currently showing up.

With April 28, 2026 approaching, the practical cost of DEA's silence won't land on the agency itself. It'll land on state regulators trying to update statutes on short notice and on licensed operators trying to figure out whether their business model still qualifies for federal registration -- people who had no hand in writing the rule and very little say in how, or whether, it gets explained to them.